Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is going to be an exciting couple of months to say the least
Seems like a person with all this experience in money should be able to get financing
Mr. Palmin has been President, CFO and Director of Novelos Therapeutics since 1998, and Acting CEO since January 2005. He was elected CEO in October 2005. Prior to joining Novelos, Mr. Palmin was Vice President, Lehman Brothers from 1996 to 1998 and was responsible for sales, product and risk management in Private Client Services. He was an Associate at Morgan Stanley & Co. from 1993 to 1996. Mr. Palmin has a B.A. degree in Economics and Business, magna cum laude, and an M.A. degree in International Economics and Finance from the International Business School at Brandeis University. He has studied at the London School of Economics and the Copenhagen Business School. Mr. Palmin is fluent in Russian and English.
Great thinking Obi-Wan Kenobi I your trusted Grasshopper looks forward to what you find LOL Please post
I have almost 400k shares that say it is going up
Newbies always say "Wish I could of got in at that price " Well here is THAT PRICE. EVCA did the same thing and look where it went
Key word is up
I like my thought process better LOL still thanks for the imput just a waiting process now
Thats what I was thinking ( why file if they are going bust) maybe something is up. Still buying 380k plus shares
And whats this mean anyone ??
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___)
NOVELOS THERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $0.00001 PAR VALUE PER SHARE
--------------------------------------------------------------------------------
(Title of Class of Securities)
67000M100
--------------------------------------------------------------------------------
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s)
--------------------------------------------------------------------------------
CUSIP No. 67000M100 13G Page 2 of 4 Pages
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Longview Fund L.P.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) ¨
(b) ¨
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
California
--------------------------------------------------------------------------------
5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 44,413,360 Shares
--------------------------------------------------------------------------------
6. SHARED VOTING POWER - None
--------------------------------------------------------------------------------
7. SOLE DISPOSITIVE POWER – 44,413,360 Shares
--------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER - None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON –
44,413,360 Shares
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.63%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
OO
--------------------------------------------------------------------------------
CUSIP No. 67000M100 13G Page 3 of 4 Pages
ITEM 1 (a) NAME OF ISSUER: Novelos Therapeutics, Inc.
ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
One Gateway Center, Suite 504, Newton, Massachusetts 02458
ITEM 2 (a) NAME OF PERSON FILING: Longview Fund L.P.
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
505 Sansome Street, Suite 1275, San Francisco, CA 94111
ITEM 2 (c) CITIZENSHIP: California
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.00001 par value
ITEM 2 (e) CUSIP NUMBER: 67000M100
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 44,413,360 Shares
(b) PERCENT OF CLASS: 8.63%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
44,413,360 Shares
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
44,413,360 Shares
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0 Shares
--------------------------------------------------------------------------------
CUSIP No. 67000M100 13G Page 4 of 4 Pages
ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable
ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP
Not applicable
ITEM 9 NOTICE OF DISSOLUTION OF GROUP
Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 14, 2011
(Date)
/s/ S. Michael Rudolph
(Signature)
S. Michael Rudolph, CFO of Viking Asset
Management LLC, as Investment Manager
(Name/Title)
The bright side is I am only down $4k this month LOL
Made alot on ACTC when the same thing happened maybe it will do it here
Call me crazy but I am buying
NOT LOOKING GOOD HERE CAN SOMEONE THROW ME A LIFE RAFT LOL
I agree and am hoping for some good news as I continue to buy
Anyone knows what this means???
As filed with the Securities and Exchange Commission on February 4, 2011
Registration No. 333-161922
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
Post-Effective Amendment No. 2 to
FORM S-1
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
______________
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation or organization) 2834
(Primary Standard Industrial
Classification Code Number) 04-3321804
(I.R.S. employer
identification number)
One Gateway Center
Suite 504
Newton, Massachusetts 02458
(617) 244-1616
(Address and telephone number of principal executive offices)
Harry S. Palmin
President and Chief Executive Officer
Novelos Therapeutics, Inc.
One Gateway Center, Suite 504
Newton, Massachusetts 02458
(617) 244-1616
(Name, address and telephone number of agent for service)
Copy to:
Paul Bork, Esq.
Foley Hoag LLP
155 Seaport Boulevard
Boston, Massachusetts 02110
(617) 832-1000
________________
Approximate date of commencement of proposed sale to the public: Not applicable.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 (“Securities Act”), check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer ¨ Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company x
(Do not check if a smaller reporting company)
--------------------------------------------------------------------------------
DEREGISTRATION OF UNSOLD SECURITIES
--------------------------------------------------------------------------------
On September 15, 2009, Novelos Therapeutics, Inc. (the "Company") filed a Registration Statement on Form S-1 (File No. 333-161922) with the Securities and Exchange Commission (the "Commission"), which was declared effective on February 12, 2010 and subsequently amended by Post-Effective Amendment No. 1 filed on April 14, 2010 (the "Registration Statement"). The Registration Statement initially registered the resale, from time to time, of 19,000,000 shares (the "Shares") of the Company's common stock, par value $0.00001 per share. The Shares were registered to permit resales of such Shares by the selling stockholders, as named in the Registration Statement, who acquired preferred stock convertible into Shares in connection with the Company's private placements of the Company’s Series E preferred stock in 2009.
In accordance with the undertaking of the Company contained in the Registration Statement pursuant to Item 512 of Regulation S-K, the Company is filing this Post-Effective Amendment No. 2 to the Registration Statement to deregister the Shares that were previously registered under the Registration Statement, 15,601,703 of which remain, to the best of the Registrant’s knowledge based on the information available to it, unsold as of the date hereof. The Company is seeking to deregister these Shares because its obligations to keep the Registration Statement effective pursuant to the terms of its registration rights agreements with the selling stockholders have terminated with respect to all the Shares. The Registration Statement is hereby amended to effect the deregistration of these 15,601,703 Shares.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this post-effective amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Newton, Commonwealth of Massachusetts, on February 4, 2011.
NOVELOS THERAPEUTICS, INC.
By: /s/ Harry S. Palmin
February 4, 2011 Harry S. Palmin
President and Chief Executive Officer
In accordance with the requirements of the Securities Act of 1933, this post-effective amendment to the registration statement was signed by the following persons in the capacities and on the dates stated:
Signature Title Date
/s/ Harry S. Palmin Chief Executive Officer and Director February 4, 2011
Harry S. Palmin ( principal executive officer )
/s/ Joanne M. Protano Chief Financial Officer February 4, 2011
Joanne M. Protano ( principal financial officer and principal accounting officer)
/s/ * Chairman of the Board of Directors February 4, 2011
Stephen A. Hill
/s/ * Director February 4, 2011
Michael J. Doyle
/s/ * Director February 4, 2011
Sim Fass
/s/ * Director February 4, 2011
James S. Manuso
/s/ * Director February 4, 2011
David B. McWilliams
/s/ * Director February 4, 2011
Howard M. Schneider
* /s/ Harry S. Palmin as attorney-in-fact.
I am sorry to hear that
If we are putting in request I bought 300k before close at 6 so lets "GET HER DONE" LOL
Ok guys you can let her run I got loaded up again LOL
Looks like a good time to aquire some shares now
I can assure you that was not GD selling
Because thats what the average "JOE" wants to hear LOL I guess cause they sure talk about it alot
Then why did you buy???
Lower you asking price always works well
I am starting to feel like the Lone Ranger here buying
Take a look at some Q & A on MCLN's website
http://www.medcleantechnologies.com/q-a-with-medclean-technologies-ceo-david-j-laky
Absolutely just have to play the waiting game
I understand and sympathize but company should be profitable this year so yes it is a gamble but like they say buy low sell high. I see it as a good investment not a gamble.
Its hard to understand why investors buy stocks when they are running up but cannot invest when they are so low. Myself I tend to put my money in a real company (like MCLN ) and wait however long for the run up. A $5000 buy in now can net a $50,000 pay out. Its done it before and most likely will again just need to be patient.
WELL SAID
Been over a year since I sold maybe old CAPTAIN JACK can make me some money again LOL calling Capt. please man the helm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57977567
Dont post here but BS is BS no matter how you step in it
Yep there is a rumor (use that term loosely by the way) that this should hit big soon so i got in early for the ride just hope it dont take all week
How does gsic tie in with roye any clues
Less than 20 million shares this thing could really get going, may see 15 cents latter today
LOL THE FIRST TO SHOW UP THATS GOOD NOW I WILL WAIT FOR THE DOUGH TO SHOW UP //// HERE DOUGH BOY LOL
ROTFLMAO WHAT A CLIQUE
JUST HAVE TO KEEP BUYING LOL
Thanks I'm in for 1.5 ml shares